Aldose reductase inhibitors and their potential for the treatment of diabetic complications
Aldose reductase converts glucose to sorbitol, which is further processed to fructose. The enzyme is present in most tissues and its possible physiological role is to produce an electrically neutral, non-diffusible osmolyte in cells exposed to hypertonicity, as typified by the renal medullary cells...
Gespeichert in:
Veröffentlicht in: | Trends in Pharmacological Sciences 1994-08, Vol.15 (8), p.293-297 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 297 |
---|---|
container_issue | 8 |
container_start_page | 293 |
container_title | Trends in Pharmacological Sciences |
container_volume | 15 |
creator | Tomlinson, David R. Stevens, Elizabeth J. Diemel, Lara T. |
description | Aldose reductase converts glucose to sorbitol, which is further processed to fructose. The enzyme is present in most tissues and its possible physiological role is to produce an electrically neutral, non-diffusible osmolyte in cells exposed to hypertonicity, as typified by the renal medullary cells of the loop of Henlé. The enzyme has a low affinity for glucose, and under normal conditions it processes tittle substrate. However, in diabetes mellitus, the marked rise in intracellular glucose that occurs in some cells causes-narked production of sorbitol. The increased flux and accumulation of sorbitol is damaging to cells and may result in some of the long-term complications of diabetes. In this review.
David Tomlinson, Elizabeth Stevens and Lara Diemel discuss the role of aldose reductase and the potential of its inhibitors as therapeutic agents targeted at chronic diabetic complications. |
doi_str_mv | 10.1016/0165-6147(94)90010-8 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76777837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0165614794900108</els_id><sourcerecordid>76777837</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-d4bbf36358c7d290e8d4d696958fdf5b786518137cdd056e8aee5a2a862e86703</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMouq7-A4UcRPRQTZo2HxdBFr9A8KInDyFNphhpmzXJCv57W3fZo4dhhnfeeRkehE4ouaKE8uux6oLTSlyo6lIRQkkhd9CMSsEKJli9i2ZbywE6TOmTEMJYSffRvlAVUUrM0Ptt50ICHMGtbDbj5IcP3_gcYsJmcDh_gI94GTIM2ZsOtyFOGs4RTO5HEYcWO28ayN5iG_pl563JPgzpCO21pktwvOlz9HZ_97p4LJ5fHp4Wt8-FZZLnwlVN0zLOammFKxUB6SrHFVe1bF1bN0LymkrKhHWO1BykAahNaSQvQXJB2Bydr3OXMXytIGXd-2Sh68wAYZW04EIIOSKZo2pttDGkFKHVy-h7E380JXpiqidgegKmVaX_mGo5np1u8ldND257tIE47s82e5Os6dpoBuvT1lZRJWU5xdysbTCy-PYQdbIeBgvOR7BZu-D__-MXgxCTdg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76777837</pqid></control><display><type>article</type><title>Aldose reductase inhibitors and their potential for the treatment of diabetic complications</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Tomlinson, David R. ; Stevens, Elizabeth J. ; Diemel, Lara T.</creator><creatorcontrib>Tomlinson, David R. ; Stevens, Elizabeth J. ; Diemel, Lara T.</creatorcontrib><description>Aldose reductase converts glucose to sorbitol, which is further processed to fructose. The enzyme is present in most tissues and its possible physiological role is to produce an electrically neutral, non-diffusible osmolyte in cells exposed to hypertonicity, as typified by the renal medullary cells of the loop of Henlé. The enzyme has a low affinity for glucose, and under normal conditions it processes tittle substrate. However, in diabetes mellitus, the marked rise in intracellular glucose that occurs in some cells causes-narked production of sorbitol. The increased flux and accumulation of sorbitol is damaging to cells and may result in some of the long-term complications of diabetes. In this review.
David Tomlinson, Elizabeth Stevens and Lara Diemel discuss the role of aldose reductase and the potential of its inhibitors as therapeutic agents targeted at chronic diabetic complications.</description><identifier>ISSN: 0165-6147</identifier><identifier>EISSN: 1873-3735</identifier><identifier>DOI: 10.1016/0165-6147(94)90010-8</identifier><identifier>PMID: 7940997</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Aldehyde Reductase - antagonists & inhibitors ; Animals ; Biological and medical sciences ; Diabetes Complications ; Diabetes Mellitus - enzymology ; Diabetes Mellitus - therapy ; Diabetic Nephropathies - drug therapy ; Diabetic Neuropathies - drug therapy ; Diabetic Retinopathy - drug therapy ; Hormones. Endocrine system ; Humans ; Medical sciences ; Pharmacology. Drug treatments</subject><ispartof>Trends in Pharmacological Sciences, 1994-08, Vol.15 (8), p.293-297</ispartof><rights>1994</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-d4bbf36358c7d290e8d4d696958fdf5b786518137cdd056e8aee5a2a862e86703</citedby><cites>FETCH-LOGICAL-c386t-d4bbf36358c7d290e8d4d696958fdf5b786518137cdd056e8aee5a2a862e86703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0165-6147(94)90010-8$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>313,314,780,784,792,3541,27913,27915,27916,45986</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4198828$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7940997$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tomlinson, David R.</creatorcontrib><creatorcontrib>Stevens, Elizabeth J.</creatorcontrib><creatorcontrib>Diemel, Lara T.</creatorcontrib><title>Aldose reductase inhibitors and their potential for the treatment of diabetic complications</title><title>Trends in Pharmacological Sciences</title><addtitle>Trends Pharmacol Sci</addtitle><description>Aldose reductase converts glucose to sorbitol, which is further processed to fructose. The enzyme is present in most tissues and its possible physiological role is to produce an electrically neutral, non-diffusible osmolyte in cells exposed to hypertonicity, as typified by the renal medullary cells of the loop of Henlé. The enzyme has a low affinity for glucose, and under normal conditions it processes tittle substrate. However, in diabetes mellitus, the marked rise in intracellular glucose that occurs in some cells causes-narked production of sorbitol. The increased flux and accumulation of sorbitol is damaging to cells and may result in some of the long-term complications of diabetes. In this review.
David Tomlinson, Elizabeth Stevens and Lara Diemel discuss the role of aldose reductase and the potential of its inhibitors as therapeutic agents targeted at chronic diabetic complications.</description><subject>Aldehyde Reductase - antagonists & inhibitors</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Diabetes Complications</subject><subject>Diabetes Mellitus - enzymology</subject><subject>Diabetes Mellitus - therapy</subject><subject>Diabetic Nephropathies - drug therapy</subject><subject>Diabetic Neuropathies - drug therapy</subject><subject>Diabetic Retinopathy - drug therapy</subject><subject>Hormones. Endocrine system</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><issn>0165-6147</issn><issn>1873-3735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMouq7-A4UcRPRQTZo2HxdBFr9A8KInDyFNphhpmzXJCv57W3fZo4dhhnfeeRkehE4ouaKE8uux6oLTSlyo6lIRQkkhd9CMSsEKJli9i2ZbywE6TOmTEMJYSffRvlAVUUrM0Ptt50ICHMGtbDbj5IcP3_gcYsJmcDh_gI94GTIM2ZsOtyFOGs4RTO5HEYcWO28ayN5iG_pl563JPgzpCO21pktwvOlz9HZ_97p4LJ5fHp4Wt8-FZZLnwlVN0zLOammFKxUB6SrHFVe1bF1bN0LymkrKhHWO1BykAahNaSQvQXJB2Bydr3OXMXytIGXd-2Sh68wAYZW04EIIOSKZo2pttDGkFKHVy-h7E380JXpiqidgegKmVaX_mGo5np1u8ldND257tIE47s82e5Os6dpoBuvT1lZRJWU5xdysbTCy-PYQdbIeBgvOR7BZu-D__-MXgxCTdg</recordid><startdate>19940801</startdate><enddate>19940801</enddate><creator>Tomlinson, David R.</creator><creator>Stevens, Elizabeth J.</creator><creator>Diemel, Lara T.</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19940801</creationdate><title>Aldose reductase inhibitors and their potential for the treatment of diabetic complications</title><author>Tomlinson, David R. ; Stevens, Elizabeth J. ; Diemel, Lara T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-d4bbf36358c7d290e8d4d696958fdf5b786518137cdd056e8aee5a2a862e86703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Aldehyde Reductase - antagonists & inhibitors</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Diabetes Complications</topic><topic>Diabetes Mellitus - enzymology</topic><topic>Diabetes Mellitus - therapy</topic><topic>Diabetic Nephropathies - drug therapy</topic><topic>Diabetic Neuropathies - drug therapy</topic><topic>Diabetic Retinopathy - drug therapy</topic><topic>Hormones. Endocrine system</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tomlinson, David R.</creatorcontrib><creatorcontrib>Stevens, Elizabeth J.</creatorcontrib><creatorcontrib>Diemel, Lara T.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in Pharmacological Sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tomlinson, David R.</au><au>Stevens, Elizabeth J.</au><au>Diemel, Lara T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aldose reductase inhibitors and their potential for the treatment of diabetic complications</atitle><jtitle>Trends in Pharmacological Sciences</jtitle><addtitle>Trends Pharmacol Sci</addtitle><date>1994-08-01</date><risdate>1994</risdate><volume>15</volume><issue>8</issue><spage>293</spage><epage>297</epage><pages>293-297</pages><issn>0165-6147</issn><eissn>1873-3735</eissn><abstract>Aldose reductase converts glucose to sorbitol, which is further processed to fructose. The enzyme is present in most tissues and its possible physiological role is to produce an electrically neutral, non-diffusible osmolyte in cells exposed to hypertonicity, as typified by the renal medullary cells of the loop of Henlé. The enzyme has a low affinity for glucose, and under normal conditions it processes tittle substrate. However, in diabetes mellitus, the marked rise in intracellular glucose that occurs in some cells causes-narked production of sorbitol. The increased flux and accumulation of sorbitol is damaging to cells and may result in some of the long-term complications of diabetes. In this review.
David Tomlinson, Elizabeth Stevens and Lara Diemel discuss the role of aldose reductase and the potential of its inhibitors as therapeutic agents targeted at chronic diabetic complications.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>7940997</pmid><doi>10.1016/0165-6147(94)90010-8</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0165-6147 |
ispartof | Trends in Pharmacological Sciences, 1994-08, Vol.15 (8), p.293-297 |
issn | 0165-6147 1873-3735 |
language | eng |
recordid | cdi_proquest_miscellaneous_76777837 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Aldehyde Reductase - antagonists & inhibitors Animals Biological and medical sciences Diabetes Complications Diabetes Mellitus - enzymology Diabetes Mellitus - therapy Diabetic Nephropathies - drug therapy Diabetic Neuropathies - drug therapy Diabetic Retinopathy - drug therapy Hormones. Endocrine system Humans Medical sciences Pharmacology. Drug treatments |
title | Aldose reductase inhibitors and their potential for the treatment of diabetic complications |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T20%3A28%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aldose%20reductase%20inhibitors%20and%20their%20potential%20for%20the%20treatment%20of%20diabetic%20complications&rft.jtitle=Trends%20in%20Pharmacological%20Sciences&rft.au=Tomlinson,%20David%20R.&rft.date=1994-08-01&rft.volume=15&rft.issue=8&rft.spage=293&rft.epage=297&rft.pages=293-297&rft.issn=0165-6147&rft.eissn=1873-3735&rft_id=info:doi/10.1016/0165-6147(94)90010-8&rft_dat=%3Cproquest_cross%3E76777837%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76777837&rft_id=info:pmid/7940997&rft_els_id=0165614794900108&rfr_iscdi=true |